Group items tagged

Earnings can often be the best indicator of a company's health and the likelihood it has to continue on a given trajectory. These three companies appear to be primed for continued strength.

As the first new Lupus drug to debut in the last half-of-a-century, Benlysta has the potential to be something special. Reception of the drug from doctors has been lukewarm thus far, but with many other treatments associated with severe potential side effects, Benlysta may be a blockbuster nonetheless.

General Cannabis licensing agreement with SC Labs has already caught the attention of several dispensaries looking to offer potency results for their strains.